Skip to content

Diffusion-tensor Imaging in Brain Tumors Evaluation

Contribution of Diffusion Tensor Imaging and Tractography in Primary and Secondary Brain Tumors Evaluation

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05261724
Enrollment
100
Registered
2022-03-02
Start date
2021-02-15
Completion date
2022-03-14
Last updated
2022-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffusion Tensor Imaging, MRI, Tractography

Brief summary

Primary and secondary brain tumors are challenging pathologies regarding diagnosis and treatment. MRI is widely used in the imaging evaluation and surgical planning, due to its spatial resolution and ability of tissular characterization. In this study patients with suspected brain tumors, confirmed by routine MRI evaluation (T1, T2, T2\*, FLAIR, T1 with contrast sequences) will undergo DWI and DTI evaluation. By analyzing collected data from MRI evaluation and patient records regarding surgical and histopathological data our aim is to investigate derived imaging biomarkers with impact in the surgical planning and rehabilitation of the patients.

Interventions

DIAGNOSTIC_TESTMRI

In this study patients with suspected primary and secondary brain tumors, confirmed by routine MRI evaluation (T1, T2, T2\*, FLAIR, T1 with contrast sequences) will undergo DWI and DTI evaluation.

Sponsors

George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of Targu Mures
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* brain tumors confirmed by routine MRI evaluation * surgical treatment with histopathological diagnosis

Exclusion criteria

* MRI contraindications * past or present neurological or neurosurgical condition, beside the tumor * pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Tract damage3 monthsAssess the damage of tracts at baseline preoperative

Secondary

MeasureTime frameDescription
Craniotomy size3 monthsAssess the size of craniotomy in patients with postoperative CT follow-up

Countries

Romania

Contacts

Primary ContactMihail Porutiu
mihai.nobel@gmail.com+40722694996
Backup ContactMircea Buruian
mircea.buruian@umfst.ro+40744503331

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026